Intra-Cellular Therapies promotes Michael Halstead to President; CFO Hineline to retire

Intra-Cellular Therapies, Inc.

Michael Halstead, former EVP & General Counsel, promoted to President effective March 19, 2024.
Halstead's base salary increased to $636,540; receives 36,717 time-based RSUs and 12,240 performance-based RSUs.
CFO Lawrence Hineline intends to retire after 20+ years; company has initiated external search for successor.
Hineline will remain through transition; departure not due to any disagreement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael I. Halstead

President

Intra-Cellular Therapies, Inc.

Effective: 2024-03-19
Filed: March 19, 2024, 7:59 PM ET

On March 19, 2024, Intra-Cellular Therapies, Inc. (the “Company”) announced that the Company promoted Michael I. Halstead, the Company’s Executive Vice President, General Counsel and Secretary, to the role of President, effective immediately.

Departed

Lawrence J. Hineline

Chief Financial Officer

Intra-Cellular Therapies, Inc.

Filed: March 19, 2024, 7:59 PM ET

On March 14, 2024, Lawrence J. Hineline notified the Company that he intends to retire as Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary of the Company following the appointment of his successor as Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael I. Halstead was appointed as President at Intra-Cellular Therapies, Inc..

Action: promoted
Role: President

Exact text from the filing

On March 19, 2024, Intra-Cellular Therapies, Inc. (the “Company”) announced that the Company promoted Michael I. Halstead, the Company’s Executive Vice President, General Counsel and Secretary, to the role of President, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lawrence J. Hineline departed as Chief Financial Officer at Intra-Cellular Therapies, Inc..

Action: intends to retire
Role: Chief Financial Officer

Exact text from the filing

On March 14, 2024, Lawrence J. Hineline notified the Company that he intends to retire as Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary of the Company following the appointment of his successor as Chief Financial Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-070838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.